Malcolm A Martin

List of Publications by Year
in descending order

39 papers	4,456 citations	186265 28 h-index	302126 39 g-index
39 all docs	39 docs citations	39 times ranked	4088 citing authors

#	Article	IF	Citations
1	Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer. Nature Communications, 2022, 13, 732.	12.8	19
2	Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia. Journal of Experimental Medicine, 2021, 218, .	8.5	31
3	Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging. Journal of Clinical Investigation, 2021, 131, .	8.2	1
4	Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope. Npj Vaccines, 2021, 6, 126.	6.0	2
5	Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Science Translational Medicine, 2021, 13, eabk1533.	12.4	27
6	Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent <scp>d</scp> -peptide HIV entry inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22436-22442.	7.1	15
7	A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. ELife, 2020, 9, .	6.0	10
8	Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature, 2019, 570, 468-473.	27.8	145
9	A single injection of crystallizable fragment domainâ€“modified antibodies elicits durable protection from SHIV infection. Nature Medicine, 2018, 24, 610-616.	30.7	94
10	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathogens, 2018, 14, e1006860.	4.7	68
11	Early antibody therapy can induce long-lasting immunity to SHIV. Nature, 2017, 543, 559-563.	27.8	244
12	Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1. Cell Host and Microbe, 2017, 22, 207-216.	11.0	60
13	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathogens, 2017, 13, e1006148.	4.7	51
14	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature, 2016, 533, 105-109.	27.8	281
15	DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV. Journal of Immunology, 2016, 197, 3999-4013.	0.8	33
16	Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates. Journal of Virology, 2016, 90, 11062-11074.	3.4	12
17	Quality and quantity of T _{FH} cells are critical for broad antibody development in SHIV _{AD8} infection. Science Translational Medicine, 2015, 7, 298ra120.	12.4	119
18	The Expression of Functional Vpx during Pathogenic SIVmac Infections of Rhesus Macaques Suppresses SAMHD1 in CD4+ Memory T Cells. PLoS Pathogens, 2015, 11, e1004928.	4.7	21

#	Article	IF	Citations
19	Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization. Nature Communications, 2015, 6, 6565.	12.8	77
20	Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. Journal of Experimental Medicine, 2014, 211, 2361-2372.	8.5	79
21	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. Journal of Experimental Medicine, 2014, 211, 2061-2074.	8.5	297
22	Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature, 2013, 503, 277-280.	27.8	424
23	Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. Science, 2013, 340, 751-756.	12.6	213
24	Most rhesus macaques infected with the CCR5-tropic SHIV _{AD8} generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19769-19774.	7.1	72
25	Rapid development of glycan-specific, broad, and potent antiâ€“HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20125-20129.	7.1	83
26	Generation of the Pathogenic R5-Tropic Simian/Human Immunodeficiency Virus SHIV _{AD8} by Serial Passaging in Rhesus Macaques. Journal of Virology, 2010, 84, 4769-4781.	3.4	78
27	Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies. Journal of Virology, 2002, 76, 2123-2130.	3.4	157
28	Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13813-13818.	7.1	22
29	Quantification of thymic function by measuring T cell receptor excision circles within peripheral blood and lymphoid tissues in monkeys. European Journal of Immunology, 2000, 30, 1145-1153.	2.9	76
30	Effect of ABC transporters on HIVâ€1 infection: inhibition of virus production by theMDR1transporter. FASEB Journal, 2000, 14, 516-522.	0.5	87
31	Short- and Long-Term Clinical Outcomes in Rhesus Monkeys Inoculated with a Highly Pathogenic Chimeric Simian/Human Immunodeficiency Virus. Journal of Virology, 2000, 74, 6935-6945.	3.4	71
32	Telomere dynamics in monkeys: Increased cell turnover in macaques infected with chimeric simianâ€human immunodeficiency viruses. Journal of Medical Primatology, 1999, 28, 1-10.	0.6	8
33	Neutralizing antibody directed against the HIVâ€“1 envelope glycoprotein can completely block HIVâ€“1/SIV chimeric virus infections of macaque monkeys. Nature Medicine, 1999, 5, 204-210.	30.7	535
34	Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cellâ€“free virions from blood plasma. Nature Medicine, 1999, 5, 211-216.	30.7	164
35	CD4+ cell turnover. Nature, 1995, 375, 194-195.	27.8	51
36	HIV-1 infection of non-dividing cells. Nature, 1994, 369, 107-108.	27.8	105

#	Article	IF	Citations
37	Fast-acting slow viruses. Nature, 1990, 345, 572-573.	27.8	18
38	The HIV A (sor) gene product is essential for virus infectivity. Nature, 1987, 328, 728-730.	27.8	505
39	mRNA transcripts related to full-length endogenous retroviral DNA in human cells. Nature, 1983, 306, 604-607.	27.8	101